Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
Seventeen patients treated for a mean period of 9-4 months with an enteric-coated form of L-dopa (Prodopa), obtained the usual spectrum of benefit as from conventional L-dopa. There was a significant dose-sparing effect with the use of the enteric-coated prepartion of the order of 40% to 50%, whilst reducing gastrointestinal side effects to a minimum, at the same time as achieving optimal clinicl benefit. Enteric-coated L-dopa appears to be a useful and welcome addition to the therapeutic armamentarium for Parkinson's disease.
D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013608:Tablets, Enteric-Coated
D013608:Tablets, Enteric-Coated; D007980:Levodopa